IDEAYA Biosciences, Inc. (IDYA)

Every figure this model derived for IDYA, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 2,208,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 828,955,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 864,025,000 AssetsCurrent 2026-06-30
current liabilities 82,677,000 LiabilitiesCurrent 2026-06-30
equity 1,198,905,000 StockholdersEquity 2026-06-30
interest expense 0 InterestPaidNet 2025-12-31
ocf -111,663,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 234,127,000 RevenueFromContractWithCustomerExcludingAssessedTax 2026-06-30
sbc 55,204,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up IDYA on one particular measure came for.

RatioValue
cash operating margin-67.91
current ratio10.51
current ratio reported10.45
dilution pct8.34
fcf margin-48.64
growth cv2.0
operating margin-92.66
owner earnings margin-72.22
revenue growth3244.67
revenue growth per share2987.2
roic-46.33
rule of 403152.01
sbc pct revenue23.58

What to be careful about

What this model itself distrusts about IDYA's figures. Written by the derivation as it ran, not added afterwards.